Search

Displaying results 2441 - 2450 of 2674 in total
  1. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    Approvals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).

  2. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,

    Categories: Vascular Endothelial Growth Factor Receptor 2 Antagonist, VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors
  3. Target

    Tyrosine-protein kinase Mer

    go.drugbank.com/bio_entities/BE0004271
    TargetHumans

    Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6.

    Synonyms: Receptor tyrosine kinase MerTK
  4. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

  5. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  6. Target

    Proto-oncogene tyrosine-protein kinase ROS

    go.drugbank.com/bio_entities/BE0009534
    TargetHumans

    Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. NELL2 is an endogenous ligand for ROS1.

    Synonyms: c-Ros receptor tyrosine kinase, Receptor tyrosine kinase c-ros oncogene 1
  7. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer [L1295]. … Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant

    Categories: Androgen Receptor Inhibitors
  8. Drug

    AK106-001616

    go.drugbank.com/drugs/DB16058
    Investigational

    AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).

  9. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. … A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  10. Target

    Sodium-dependent phosphate transporter 1

    go.drugbank.com/bio_entities/BE0005055
    TransporterHumans

    Sodium-phosphate symporter which preferentially transports the monovalent form of phosphate with a stoichiometry of two sodium ions per phosphate ion (PubMed:11009570, PubMed:16790504, PubMed:17494632, PubMed:19726692, PubMed:7929240, Pu...

    Synonyms: Leukemia virus receptor 1 homolog, Gibbon ape leukemia virus receptor 1